ERBB2 and breast cancer: Among the downstream effectors of EGFR, PI3K and AKT activities are significantly increased in triple-negative (ERα-/PR-/HER2-) breast cancers [40, 41], and PI3K expression is associated with poor prognosis in breast cancer [42].